China SXT Pharmaceuticals (NASDAQ:SXTC) Upgraded to Sell at Wall Street Zen

Posted by Stacy Sanders on Feb 8th, 2026

Wall Street Zen upgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC – Free Report) to a sell rating in a research note released on Saturday morning.

China SXT Pharmaceuticals Price Performance

SXTC opened at $3.00 on Friday. The company’s 50 day moving average is $136.56 and its 200 day moving average is $197.23. China SXT Pharmaceuticals has a 12-month low of $2.63 and a 12-month high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last released its quarterly earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share for the quarter. The business had revenue of $0.31 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC lifted its stake in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Free Report) by 107.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,983 shares of the company’s stock after acquiring an additional 15,013 shares during the quarter. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 at the end of the most recent reporting period. Institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.